Lesson 25

1. What type of clinical trial was used?

• Phase 1b, randomized, double-blind

• Phase 2, non-randomized, uncontrolled, single-blind

• Phase 1b, randomized, placebo-controlled, single-blind

• Phase 2, randomized, placebo-controlled, double-blind

2. What was the primary endpoint?

• Appetite and cachexia symptoms

• Change from baseline in body weight

• Digital measures of physical activity

• Safety

3. Which group had a median difference of 2.81 kg of weight gain as compared to the placebo group?

• Ponsegromab 100 mg

• Ponsegromab 200 mg

• Ponsegromab 400 mg

• All the ponsegromab groups

4. How many patients experienced adverse effects of any cause?

• 80% in the ponsegromab groups and 70% in the placebo group

• 22 to 40% in the ponsegromab groups and 24% in the placebo group

• 4 to 11% in the ponsegromab groups and 9% in the placebo group

• 67 to 74% in the ponsegromab groups and 80% in the placebo group

5. What type of clinical trial was used?

• Phase 2b randomized, double-blind, placebo-controlled trial

• Phase 2a randomized, double-blind, uncontrolled trial

• Phase 2a randomized, double-blind, placebo-controlled trial

• Phase 2a randomized, single-blind, placebo-controlled trial

6. What was the primary endpoint?

• Relative liver fat change

• Change in body weight change at 24 weeks

• Change in insulin sensitivity and lipid metabolism

• Change in visceral adipose tissue

7. The relative percentage of hepatic fat fraction in the 8 mg RETA at 48 weeks was?

• -57.0%

• -81.4%

• -81.7%

• -86.0%

8. Which answer is INCORRECT?

• The safety profile of retatrutide in people with MASLD was similar to that observed previous trials of people with obesity

• There were no hepatotoxicity signals in the overall obesity trial population or in the subset of participants with MASLD through 48 weeks

• Several cases of patients with advanced fibrosis or cirrhosis in the group with the higher doses of RETA were reported

• Mild-to-moderate gastrointestinal events were the most frequently reported adverse events